文献速递MDS 与骨髓增殖性肿瘤

Janus激酶-2抑制剂非德拉替尼治疗既往接受芦可替尼治疗的骨髓纤维化患者(JAKARTA-2):单臂、开放标签、非随机、2期、多中心研究

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
PubMed 文献 · Lancet Haematol · 2017-06-08

JAKARTA-2研究在9国31个中心入组97例芦可替尼耐药或不耐受的骨髓纤维化患者,接受非德拉替尼400mg每日一次口服治疗。83例可评估患者中46例(55%,95%CI 44-66)达到脾脏缓解,常见3-4级不良事件为贫血(38%)和血小板减少(22%)。研究达到主要终点,但存在潜在毒性,需进一步评估。

要点

  • 芦可替尼耐药或不耐受的骨髓纤维化患者中,非德拉替尼脾脏缓解率为55%(95%CI 44-66)。
  • 常见3-4级不良事件为贫血(38%)和血小板减少(22%),19%患者因不良事件停药。
  • 研究期间7%患者死亡,均与药物无关;其他非德拉替尼试验中疑似韦尼克脑病导致本研究终止。

核心结论

  • 本2期研究达到主要终点,提示芦可替尼耐药或不耐受的骨髓纤维化患者可能从非德拉替尼获得显著临床获益,但代价是某些潜在毒性,需进一步评估。
  • 该背景下非德拉替尼的开发正在评估中。

研究设计与样本

  • 单臂、开放标签、非随机、2期、多中心研究,在9个国家31个中心进行。
  • 入组成人患者为当前诊断的中危或高危原发性骨髓纤维化、真性红细胞增多症后骨髓纤维化或原发性血小板增多症后骨髓纤维化,且至少治疗14天后判定为芦可替尼耐药或不耐受。
  • 其他主要纳入标准包括可触及的脾肿大(左肋缘下≥5 cm)、东部肿瘤协作组体能状态评分≤2、预期寿命≤6个月。
  • 患者接受非德拉替尼口服起始剂量400 mg每日一次,连续6个28天周期。
  • 主要终点为脾脏缓解(盲法中心影像实验室CT和MRI判定脾脏体积较基线减少≥35%的患者比例)。

主要发现

  • 2012年5月8日至2013年8月29日,97例患者入组并接受至少一剂非德拉替尼。
  • 83例可评估患者中,46例(55%,95%CI 44-66)达到脾脏缓解。
  • 常见3-4级不良事件包括贫血(37/97例,38%)和血小板减少(21/97例,22%),18例(19%)患者因不良事件停药。
  • 研究期间7例(7%)患者死亡,但无一例与药物相关。
  • 其他非德拉替尼试验中疑似韦尼克脑病病例导致本研究终止。

关键数值与推荐

  • 脾脏缓解定义为盲法中心影像实验室CT和MRI判定脾脏体积较基线减少≥35%。
  • 主要分析在符合方案人群中进行(接受非德拉替尼治疗且有基线及至少一次基线后脾脏体积测量的患者),安全性分析在所有接受至少一剂非德拉替尼的患者中进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 其他非德拉替尼试验中疑似韦尼克脑病病例导致本研究终止。
  • 作者指出非德拉替尼的潜在毒性需要进一步评估。
  • 该背景下非德拉替尼的开发正在评估中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myelofibrosis is a chronic myeloproliferative neoplasm characterised by splenomegaly, cytopenias, bone marrow fibrosis, and debilitating symptoms including fatigue, weight loss, and bone pain. Mutations in Janus kinase-2 (JAK2) occur in approximately 50% of patients. The only approved JAK2 inhibitor for myelofibrosis is the dual JAK1 and JAK2 inhibitor, ruxolitinib. 58-71% of patients treated with ruxolitinib in clinical trials so far have not achieved the primary endpoint of 35% or more reduction in spleen volume from baseline assessed by MRI or CT. Furthermore, more than 50% of patients discontinue ruxolitinib treatment after 3-5 years. On the basis of this unmet need, we investigated the efficacy and safety of fedratinib, a JAK2-selective inhibitor, in patients with ruxolitinib-resistant or ruxolitinib-intolerant myelofibrosis. METHODS: This single-arm, open-label, non-randomised, phase 2, multicentre study, done at 31 sites in nine countries, enrolled adult patients with a current diagnosis of intermediate or high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis, found to be ruxolitinib resistant or intolerant after at least 14 days of treatment. Other main inclusion criteria were palpable splenomegaly (≥5 cm below the left costal margin), Eastern Cooperative Oncology Group performance status of 2 or less, and life expectancy of 6 months or less. Patients received oral fedratinib at a starting dose of 400 mg once per day, for six consecutive 28-day cycles. The primary endpoint was spleen response (defined as the proportion of patients with a ≥35% reduction in spleen volume as determined by blinded CT and MRI at a central imaging laboratory). We did the primary analysis in the per-protocol population only (patients treated with fedratinib, for whom a baseline and at least one post-baseline spleen volume measurement was available) and the safety analysis in all patients receiving at least one dose of fedratinib. This trial was registered with ClinicalTrials.gov, number NCT01523171. FINDINGS: Between May 8, 2012, and Aug 29, 2013, 97 patients were enrolled and received at least one dose of fedratinib. Of 83 assessable patients, 46 (55%, 95% CI 44-66) achieved a spleen response. Common grade 3-4 adverse events included anaemia (37 [38%] of 97 patients) and thrombocytopenia (21 [22%] of 97), with 18 (19%) patients discontinuing due to adverse events. Seven (7%) patients died during the study, but none of the deaths was drug related. Suspected cases of Wernicke's encephalopathy in other fedratinib trials led to study termination. INTERPRETATION: This phase 2 study met its primary endpoint, suggesting that patients with ruxolitinib-resistant or ruxolitinib-intolerant myelofibrosis might achieve significant clinical benefit with fedratinib, albeit at the cost of some potential toxicity, which requires further evaluation. Fedratinib development in this setting is currently being assessed. FUNDING: Sanofi.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017. PMID: 28602585. doi:10.1016/S2352-3026(17)30088-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。